The substantial outperformance of Edwards Lifesciences (EW) over the past 15 years, as highlighted by its average annual return of 21.4% and the significant growth of an initial $1000 investment, underscores the stock's strong performance and potential attractiveness to investors. This historical performance, coupled with a current market capitalization of $55.88 billion, suggests a positive outlook and potential for continued growth, making it likely to attract investor interest and potentially drive up the stock price in the short term.